Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
Open Access
- 15 October 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10), 3319
- https://doi.org/10.3390/jcm9103319
Abstract
Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricitinib) in real life. Methods: All patients in the rheumatology department of Amiens University Hospital treated by JAKis for RA were included from 1 October 2017 to 20 May 2020. Clinical and biological data were provided retrospectively in this observational and single-center study. We aimed to study the JAKi maintenance rate at 12 months and their clinical and biological safety profiles. Results: Fifty-five patients were included. Drug maintenance at 12 months was 67.6%. Factors associated with poorer maintenance were a higher Charlson comorbidity index (HR 1.311 (1.089–1.579); p = 0.0042), a higher age (HR 1.055 (1.015–1.096); p = 0.0067), and corticosteroids therapy at initiation (HR 2.722 (1.006–7.365); p = 0.0487). The clinical and biological safety profile was generally good. Conclusions: Our study found that a higher Charlson index, age, and corticosteroids appeared to be associated with the earlier discontinuation of treatment. JAKis had a response and tolerance profile in real life at least equivalent to that of biological disease-modifying antirheumatic drugs (bDMARDs).This publication has 30 references indexed in Scilit:
- Baricitinib in Patients with Refractory Rheumatoid ArthritisThe New England Journal of Medicine, 2016
- A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspectiveRheumatology International, 2016
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateAnnals Of The Rheumatic Diseases, 2014
- Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in GermanyHealth Economics Review, 2014
- Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritisClinical Rheumatology, 2014
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals Of The Rheumatic Diseases, 2010
- Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatmentAnnals Of The Rheumatic Diseases, 2006
- Patients' perceptions of fatigue in rheumatoid arthritis: Overwhelming, uncontrollable, ignoredArthritis Care & Research, 2005
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987